Novel Insights from Research Practice

Gumà J.a,b,c· Peña K.B.b,c,d· Riu F.b,c,d· Lucia-Gozálvez C.a,b,c· Vidaller A.a,b,c· Maldonado V.a,b,c· Parada D.b,c,d

Author affiliations

aMedical Oncology Department, Southern Catalonia Oncology Institute, Hospital Universitari de Sant Joan, Reus, Spain
bInstitut d’Investigació Sanitària Pere Virgili, Reus, Spain
cFacultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain
dPathology Molecular Unit, Department of Pathology, Hospital Universitari de Sant Joan, Reus, Spain

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: March 23, 2022
Accepted: September 14, 2022
Published online: February 02, 2023

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 1

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Abstract

Introduction: Liquid biopsy is an innovative and efficient method for studying circulating tumor DNA. In conjunction with innovative techniques such as next-generation sequencing, it can provide real-time information on prognostic and predictive factors. Case Presentation: We report a case of advanced, unresectable medullary thyroid carcinoma with various rearranged during transfection (RET) and Kirsten rat sarcoma viral (KRAS) mutations in both blood liquid and tissue biopsies. After the initial failure of treatment with a tyrosine kinase inhibitor (TKI), a liquid biopsy analyzed by next-generation sequencing showed the presence of six different RET mutations and KRAS. Tissue biopsy also revealed two RET mutations. Due to these biopsy findings, the treatment was changed to another TKI, and the patient is now clinically stable. Discussion/Conclusion: Liquid biopsy makes it possible to analyze different genetic alterations that may have implications as predictive factors. It also reveals tumor heterogeneity and its implications for prognostic factors.

© 2023 S. Karger AG, Basel

References Pereira M, Williams VL, Hallanger Johnson J, Valderrabano P. Thyroid cancer incidence trends in the United States: association with changes in professional guideline recommendations. Thyroid. 2020 Aug;30(8):1132–40. Alapat DV, Ain KB, Sloan DA, Monaghan KG, Karabakhtsian RG. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocr. 2011 Apr;39(2):148–52. Mulder H, Silberbusch J, Hackeng WH, van der Meer C, den Ottolander GJ. Hypercalcitoninaemia in patients with chronic inflammatory disease. Neth J Med. 1980;23(3):129–31. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013 Feb;98(2):E364–9. Lorusso L, Cappagli V, Valerio L, Giani C, Viola D, Puleo L, et al. Thyroid cancers: from surgery to current and future systemic therapies through their molecular identities. Int J Mol Sci. 2021 Mar 18;22(6):3117. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011 May;96(5):E863–8. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid. 2013 Jan;23(1):50–7. Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab. 2012 Oct;97(10):E2031–5. Tay TKY, Tan PH. Liquid biopsy in breast cancer: a focused review. Arch Pathol Lab Med. 2021 Jun 1;145(6):678–86. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic: implementation issues and future challenges. Nat Rev Clin Oncol. 2021 May;18(5):297–312. Jing C, Mao X, Wang Z, Sun K, Ma R, Wu J, et al. Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer. Mol Med Rep. 2018 Aug;18(2):2191–7. Lin C, Liu X, Zheng B, Ke R, Tzeng CM. Liquid biopsy, ctDNA diagnosis through NGS. Life. 2021 Aug 28;11(9):890. Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014 Mar;14(3):173–86. Roskoski R Jr, Sadeghi-Nejad A. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacol Res. 2018 Feb;128:1–17. Santoro M, Moccia M, Federico G, Carlomagno F. RET gene fusions in malignancies of the thyroid and other tissues. Genes. 2020 Apr 15;11(4):424. Accardo G, Conzo G, Esposito D, Gambardella C, Mazzella M, Castaldo F, et al. Genetics of medullary thyroid cancer: an overview. Int J Surg. 2017 May;41(Suppl 1):S2–6. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol. 2008 Mar 12;284(1–2):21–7. Vuong HG, Odate T, Ngo HTT, Pham TQ, Tran TTK, Mochizuki K, et al. Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis. Endocr Relat Cancer. 2018 Jun;25(6):633–41. Moura MM, Cabrera RA, Esteves S, Cavaco BM, Soares P, Leite V. Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma. J Endocrinol Invest. 2021 Sep;44(9):1837–46. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, et al. Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3591–9. Romano C, Martorana F, Pennisi MS, Stella S, Massimino M, Tirrò E, et al. Opportunities and challenges of liquid biopsy in thyroid cancer. Int J Mol Sci. 2021 Jul 19;22(14):7707. Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol. 2020 Apr;15(4):541–9. Bruce JY, Bible KC, Chintakuntlawar AV. Emergence of resistant clones in medullary thyroid cancer may not Be rescued by subsequent salvage highly selective rearranged during transfection-inhibitor therapy. Thyroid. 2021 Feb;31(2):332–3. Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, et al. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 Jan;43(1):E7–12. Liu X, Hu X, Shen T, Li Q, Mooers BHM, Wu J. RET kinase alterations in targeted cancer therapy. Cancer Drug Resist. 2020 May 11;3(3):472–81. Renovanz M, Kim EL. Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. Front Oncol. 2014 Jun 10;4:142. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012 Mar 8;366(10):883–92. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010 Oct 28;467(7319):1114–7. Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn. 2017 May;19(3):341–65. Dvoráková S, Václavíková E, Sýkorová V, Dusková J, Vlcek P, Ryska A, et al. New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma. Thyroid. 2006 Mar;16(3):311–6. Chmielik E, Rusinek D, Oczko-Wojciechowska M, Jarzab M, Krajewska J, Czarniecka A, et al. Heterogeneity of thyroid cancer. Pathobiology. 2018;85(1–2):117–29. Sadow PM, Hunt JL. Mixed Medullary-follicular-derived carcinomas of the thyroid gland. Adv Anat Pathol. 2010 Jul;17(4):282–5. Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol. 2022 Mar;33(1):27–63. Appetecchia M, Lauretta R, Barnabei A, Pieruzzi L, Terrenato I, Cavedon E, et al. Epidemiology of simultaneous medullary and papillary thyroid carcinomas (MTC/PTC): an Italian multicenter study. Cancers. 2019 Oct 9;11(10):1516. Article / Publication Details

First-Page Preview

Received: March 23, 2022
Accepted: September 14, 2022
Published online: February 02, 2023

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 1

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.